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CASE REPORT
TCT 2021 CLINICAL CASE

Left Atrial Venoarterial Extracorporeal
Membrane Oxygenation for Acute Aortic
Regurgitation and Cardiogenic Shock
Michael Chiang, MBBS, Pedro E. Gonzalez, MD, Barbar Basir, DO, Brian P. O’Neill, MD, James Lee, MD,
Tiberio Frisoli, MD, Dee Dee Wang, MD, William W. O’Neill, MD, Pedro A. Villablanca, MD, MSC

ABSTRACT
A 51-year-old man with past medical history of bioprosthetic aortic valve replacement presented in cardiogenic shock
secondary to acute bioprosthesis degeneration with severe aortic regurgitation. Venoarterial extracorporeal membrane
oxygenation is contraindicated in patients with severe AI. Use of left atrial venoarterial extracorporeal membrane
oxygenation resulted in hemodynamic improvement, allowing patient stabilization for emergency valve-in-valve transcatheter aortic valve replacement. (Level of Difﬁculty: Advanced.) (J Am Coll Cardiol Case Rep 2022;4:276–279)
Published by Elsevier on behalf of the American College of Cardiology Foundation. This is an open access article under the
CC BY license (http://creativecommons.org/licenses/by/4.0/).

INTRODUCTION

indirectly unloads the LV by placement of an inﬂow
cannula in the LA and can be considered in such

Venoarterial extracorporeal membrane oxygenation
(VA-ECMO) has been globally implemented as an
emergency means for providing biventricular hemodynamic support in patients with cardiogenic shock.
VA-ECMO, however, increases left ventricular (LV)
afterload and is contraindicated in patients with severe aortic regurgitation. Left atrial (LA) venoarterial
extracorporeal membrane oxygenation (LAVA-ECMO)

patients.

HISTORY OF PRESENTATION
A 51-year-old man presented to an outside institution
with acute chest pain and shortness of breath at rest.
His systemic blood pressure was 80/30 mm Hg, and
on physical examination, he was found to have a
grade 4/6 diastolic and grade 2/6 systolic murmur at
the left upper sternal border.

LEARNING OBJECTIVES
 To understand the limitations and contraindications of various MCS devices.
 To understand the technical aspects of
LAVA-ECMO insertion.
 LAVA-ECMO is an effective option for patients with cardiogenic shock and severe
aortic regurgitation.

PAST MEDICAL HISTORY
The patient was known to have a history of infective
endocarditis requiring surgical aortic valve replacement with a 23-mm Freestyle bioprosthesis (Medtronic) with concomitant aortic root repair more than
10 years before presentation. He also had a past
medical

history

of

end-stage

renal

failure

on
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F I G U R E 1 Left Coronary Artery Angiogram

ﬁlling pressures (pulmonary capillary wedge

ABBREVIATIONS

pressure: 44 mm Hg), cardiac index of 0.96

AND ACRONYMS

2

L/min/m , pulmonary artery pulsatility index
of 1.2, and aortic valve area 0.53 m 2 (peak-topeak gradient: 25 mm Hg). With biventricular
failure, in the absence of other means of
mechanical circulatory support, an intraaortic balloon pump was inserted as a bridge
to emergency transfer to our institution for
escalation of care.
Upon arrival to the cardiac catheterization
terization demonstrated biventricular heart
with

LA = left atrial
LAVA-ECMO = left atrial
venoarterial extracorporeal
membrane oxygenation

LV = left ventricle
MCS = mechanical circulatory
support

laboratory, repeat left and right heart cathefailure

AI = aortic insufﬁciency

elevated

ﬁlling

RA = right atrial
TAVR = transcatheter aortic
valve replacement

pressures

VA-ECMO = venoarterial

(Figure 2). VA-ECMO, which is often used for

extracorporeal membrane

biventricular support, is contraindicated in

oxygenation

this patient with severe aortic insufﬁciency (AI)
because of catastrophic LV overloading. Hence,
LAVA-ECMO was implemented. LAVA-ECMO was
performed with deep sedation without general aneshemodialysis, atrial ﬁbrillation, permanent pacemaker implantation, diabetes mellitus, hypertension,
and obstructive sleep apnea.

thesia

to

avoid

risk

of

further

hemodynamic

compromise and for dynamic assessment of neurologic function. The arterial ECMO cannula was inserted in a standard fashion. Bilateral femoral venous

DIFFERENTIAL DIAGNOSIS

accesses were obtained. Intracardiac echocardiography catheter 5 was inserted into the RA via venous

The differential diagnosis included non–ST-segment

access. Intracardiac echocardiography–guided trans-

elevation myocardial infarction, severe aortic regur-

septal puncture was done via contralateral venous

gitation

bio-

access. A 0.35-mm Amplatz ExtraStiff wire was sent to

to

the left upper pulmonary vein. An 8-  40-mm pe-

degenerative aortic bioprosthesis, congestive heart

ripheral balloon was delivered via the stiff wire for

failure, and cardiogenic shock.

septostomy (Figure 3). A 24-F multifenestrated LAVA-

secondary

prosthesis,

severe

to

degenerative

aortic

stenosis

aortic

secondary

ECMO cannula was then sent across the interatrial

INVESTIGATIONS
The

electrocardiogram

septum into the LA. Biatrial and biventricular
showed

no

ST-segment

elevation. His laboratory proﬁle was remarkable for
an elevated high-sensitivity troponin I of 5.6 ng/dL,
lactate of 2.6 mmol/L, and B-type natriuretic peptide
of 1,248 pg/mL. Bedside surface echocardiogram
demonstrated a severely depressed LV ejection fraction of 20% and structural valve degeneration of the
bioprosthetic with notable mixed aortic bioprosthetic
valve

disease,

severe

aortic

regurgitation,

and

concomitant stenosis.

MANAGEMENT

unloading were feasible, with side holes opening on
both the LA and RA sides (Videos 1 and 2). Invasive
hemodynamics 30 minutes post–LAVA-ECMO procedure demonstrated an acute decrease in LV enddiastolic pressure by 16 mm Hg from the time of
presentation, an RA pressure drop to 8 mm Hg, and an
increase in cardiac index to 3.2 L/min/m 2 (Figure 2).
The patient was evaluated by the cardiothoracic
surgeons team and deemed not a surgical candidate
for redo aortic valve replacement, given his acute
cardiogenic

shock

presentation

with

concurrent

multiple comorbidities. The patient’s clinical condition stabilized over the following 24 hours with

A left heart catheterization was performed, demon-

improvement in laboratory markers. The patient was

strating severe left main bifurcation coronary artery

evaluated by the multidisciplinary structural heart

disease (Figure 1), right coronary artery chronic total

team and was recommended for percutaneous coro-

occlusion, and an LV end-diastolic pressure of

nary intervention of the left main and left anterior

35 mm Hg. Right heart catheterization was also per-

descending

formed, revealing severely elevated right heart ﬁlling

(Video 3A). Valve-in-valve transcatheter aortic valve

pressures (right atrial [RA]: 27 mm Hg) and left heart

replacement (TAVR) with a 23-mm Sapien 3 Ultra

arteries

on

day

3

after

admission
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F I G U R E 2 Hemodynamics Before and After LAVA-ECMO

CI ¼ cardiac index; CO ¼ cardiac output; CPO ¼ cardiac power output; IABP ¼ intra-aortic balloon pump; LAVA-ECMO ¼ left atrial venoarterial extracorporeal
membrane oxygenation; PAPi ¼ pulmonary artery pulsatility index.

(Edwards Lifesciences) was performed on day 5

DISCUSSION

(Video 3B). Hemodynamic assessment after valve-invalve TAVR valve deployment showed no signiﬁcant

There are limited mechanical circulatory support

perivalvular leak, and the patient was able to undergo

(MCS) options in patients presenting with cardiogenic

LAVA-ECMO decannulation on the table. Repeat

shock in the setting of biventricular failure and severe

transthoracic echocardiogram demonstrated a dra-

aortic regurgitation. VA-ECMO is contraindicated in

matic improvement in LV function and trace para-

this patient population because the increased after-

valvular leak.

load from the VA-ECMO cannulation would result in
LV dilatation, severe pulmonary edema, and the risk

F I G U R E 3 Septostomy With Peripheral Balloon Before Left

of thrombus formation in the LV. In fact, catastrophic

Atrial Venoarterial Extracorporeal Membrane Oxygenation

effects on LV function have been reported in cases

Venous Cannula Insertion

with even mild aortic regurgitation. 1 The use of 2
univentricular devices, such as Impella (Abiomed Inc)
or Tandem Heart (LivaNova), can be considered;
however, Impella is also contraindicated in patients
with severe AI, and the use of 2 devices can increase
the risk of complications and hemolysis, particularly
in patients who will require MCS support for longer
than a few days. The use of surgically implanted VAECMO with the inﬂow cannula directly placed in the
LV or the use of a biventricular ventricular assist device can also provide adequate support but comes
with the prerequisite of surgical implantation (which
is considered a prohibitive risk in patients who are
not being considered for a durable LV assist device or
transplantation). Hence, LAVA-ECMO serves as a
viable percutaneous option for such patients.
There is an ongoing increase in the global awareness of and demand for early implementation of MCS
in cardiogenic shock patients, which has been associated with improved survival. However, there
remain limitations to existing MCS technologies.
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Some forms of MCS are not readily available in an

CONCLUSIONS

emergency setting (eg, a biventricular ventricular
assist device), some are contraindicated in certain

LAVA-ECMO

clinical scenarios (eg, VA-ECMO in severe aortic

demanding, and cost-effective option for hemody-

regurgitation), and others remain expensive or

namic support in patients with cardiogenic shock and

require multiple large-bore accesses (eg, VA-ECMO

severe aortic regurgitation.

is

an

effective,

non–technically

plus Impella). LAVA-ECMO was ﬁrst described in
2018 for patients with biventricular cardiogenic
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